UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 107

Sortiert nach

Cognitive behavioural therapy for tinnitus

Cochrane database of systematic reviews, 2007-01 (1), p.CD005233

2007

Volltextzugriff (PDF)

Radiofrequency ablation in the management of liver metastases from breast cancer

American journal of roentgenology (1976), 2007-10, Vol.189 (4), p.883

2007

Volltextzugriff (PDF)

Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer

Journal of clinical oncology, 1998-10, Vol.16 (10), p.3353-3361

1998

Volltextzugriff (PDF)

PH-0493 The impact of anal VMAT on radiotherapy skin reactions

Radiotherapy and oncology, 2021-08, Vol.161, p.S377-S378

2021

Volltextzugriff (PDF)

Cardiac profiles of liposomal anthracyclines: Greater cardiac safety versus conventional doxorubicin?

Cancer, 2004-05, Vol.100 (10), p.2052-2063

2004

Volltextzugriff (PDF)

245P Palbociclib combined with aromatase inhibitors (AIs) in women ≥75 years with oestrogen receptor positive (ER+ve), human epidermal growth factor receptor 2 negative (HER2-ve) advanced breast cancer: A real-world multicentre UK study

Annals of oncology, 2021-09, Vol.32, p.S466-S466

2021

Volltextzugriff (PDF)

First cluster of vancomycin‐resistant Enterococcus faecalis isolates in Cyprus

Clinical microbiology and infection, 2005-03, Vol.11 (3), p.232-234

2005

Volltextzugriff (PDF)

Cardiac effects of adjuvant therapy for early breast cancer

Seminars in oncology, 2003-12, Vol.30 (6), p.730-739

2003

Volltextzugriff (PDF)

Phase II Study of Celecoxib and Trastuzumab in Metastatic Breast Cancer Patients Who Have Progressed after Prior Trastuzumab-Based Treatments

Clinical cancer research, 2004-06, Vol.10 (12), p.4062-4067

2004

Volltextzugriff (PDF)

Abstract P2-16-07: Phase II study of pertuzumab, trastuzumab, and weekly paclitaxel in patients with metastatic HER2-overexpressing metastatic breast cancer with cardiac biomarker data

Cancer research (Chicago, Ill.), 2013-12, Vol.73 (24_Supplement), p.P2-P2-16-07

2013

Volltextzugriff (PDF)

Pain and deliberate self-harm An important association

Journal of psychosomatic research, 2005-04, Vol.58 (4), p.317-320

2005

Volltextzugriff (PDF)

Abstract P5-18-20: Phase II study of pertuzumab, trastuzumab, and weekly paclitaxel in patients with metastatic HER2-overexpressing metastatic breast cancer

Cancer research (Chicago, Ill.), 2012-12, Vol.72 (24_Supplement), p.P5-P5-18-20

2012

Volltextzugriff (PDF)

Abstract P6-11-12: A Novel Capecitabine Schedule (7 on — 7 off) Is Feasible with Lapatinib for Patients with HER2-Positive Metastatic Breast Cancer Refractory to Trastuzumab

Cancer research (Chicago, Ill.), 2010-12, Vol.70 (24_Supplement), p.P6-P6-11-12

2010

Volltextzugriff (PDF)

Cognitive behavioural therapy for tinnitus

Archivos de prevención de riesgos laborales, 2013-04, Vol.16 (2), p.96-97

2013

Volltextzugriff (PDF)

Sequential adjuvant therapy: the Memorial Sloan-Kettering Cancer Center experience

Seminars in oncology, 1996-02, Vol.23 (1 Suppl 1), p.58

1996

Volltextzugriff (PDF)

A novel capecitabine dosing schedule combined with bevacizumab is safe and active in patients with metastatic breast cancer: a phase II study

Cancer research (Chicago, Ill.), 2009-01, Vol.69 (2_Supplement), p.6121

2009

Volltextzugriff (PDF)

Phase II Evaluation of a Novel Capecitabine Schedule in Combination with Lapatinib for Patients with HER2-Positive Metastatic Breast Cancer Refractory to Trastuzumab

Cancer research (Chicago, Ill.), 2009-12, Vol.69 (24_Supplement), p.5113-5113

2009

Volltextzugriff (PDF)

Dose-dense therapy with paclitaxel via weekly 1-hour infusion: preliminary experience in the treatment of metastatic breast cancer

Seminars in oncology, 1997-10, Vol.24 (5 Suppl 17), p.S17

1997

Volltextzugriff (PDF)

Phase II Study of Feasibility of Dose-Dense FEC Followed by Alternating Weekly Taxanes in High-Risk, Four or More Node-Positive Breast Cancer

Clinical cancer research, 2004-09, Vol.10 (17), p.5754-5761

2004

Volltextzugriff (PDF)

TBCRC 011: Targeting the androgen receptor (AR) for the treatment of AR+/ER-/PR- metastatic breast cancer (MBC)

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.TPS122-TPS122

2011

Volltextzugriff (PDF)

Safety of a novel capecitabine dosing schedule when combined with lapatinib in patients with HER2-positive metastatic breast cancer refractory to trastuzumab

Journal of clinical oncology, 2009-05, Vol.27 (15_suppl), p.1131-1131

2009

Volltextzugriff (PDF)

A novel capecitabine dosing schedule combined with bevacizumab is safe and active in patients with metastatic breast cancer: A phase II study

Journal of clinical oncology, 2008-05, Vol.26 (15_suppl), p.1101-1101

2008

Volltextzugriff (PDF)

Phase II trial of patupilone in patients (pts) with breast cancer brain metastases (BCBM) progressing or recurring after whole brain radiation therapy (WBXRT)

Journal of clinical oncology, 2008-05, Vol.26 (15_suppl), p.1086-1086

2008

Volltextzugriff (PDF)

Standard chemotherapy (CMF or AC) versus capecitabine in early-stage breast cancer (BC) patients aged 65 and older: Results of CALGB/CTSU 49907

Journal of clinical oncology, 2008-05, Vol.26 (15_suppl), p.507-507

2008

Volltextzugriff (PDF)

Phase I study of a novel capecitabine schedule based on Norton-Simon mathematical modeling

Journal of clinical oncology, 2007-06, Vol.25 (18_suppl), p.1045-1045

2007

Volltextzugriff (PDF)

1 – 25 von 107

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(93)
Mit Volltextzugriff
(88)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(54)
Life Sciences & Biomedicine
(52)
Humans
(39)
Biological And Medical Sciences
(26)
Female
(24)
Adult
(22)
Medical Sciences
(18)
Middle Aged
(15)
Aged
(14)
Breast Neoplasms - Drug Therapy
(14)
Oncology
(13)
Plant Sciences
(11)
Male
(10)
Tumors
(10)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(9)
Pharmacology. Drug Treatments
(9)
Antineoplastic Agents
(8)
Biochemistry & Molecular Biology
(8)
Fundamental And Applied Biological Sciences. Psychology
(8)
Paclitaxel - Administration & Dosage
(8)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Cognitive behavioural therapy for tinnitus

Radiofrequency ablation in the management of liver metastases from breast cancer

Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer

PH-0493 The impact of anal VMAT on radiotherapy skin reactions

Cardiac profiles of liposomal anthracyclines: Greater cardiac safety versus conventional doxorubicin?

245P Palbociclib combined with aromatase inhibitors (AIs) in women ≥75 years with oestrogen receptor positive (ER+ve), human epidermal growth factor receptor 2 negative (HER2-ve) advanced breast cancer: A real-world multicentre UK study

First cluster of vancomycin‐resistant Enterococcus faecalis isolates in Cyprus

Cardiac effects of adjuvant therapy for early breast cancer

Phase II Study of Celecoxib and Trastuzumab in Metastatic Breast Cancer Patients Who Have Progressed after Prior Trastuzumab-Based Treatments

Abstract P2-16-07: Phase II study of pertuzumab, trastuzumab, and weekly paclitaxel in patients with metastatic HER2-overexpressing metastatic breast cancer with cardiac biomarker data

Pain and deliberate self-harm An important association

Abstract P5-18-20: Phase II study of pertuzumab, trastuzumab, and weekly paclitaxel in patients with metastatic HER2-overexpressing metastatic breast cancer

Abstract P6-11-12: A Novel Capecitabine Schedule (7 on — 7 off) Is Feasible with Lapatinib for Patients with HER2-Positive Metastatic Breast Cancer Refractory to Trastuzumab

Cognitive behavioural therapy for tinnitus

Sequential adjuvant therapy: the Memorial Sloan-Kettering Cancer Center experience

A novel capecitabine dosing schedule combined with bevacizumab is safe and active in patients with metastatic breast cancer: a phase II study

Phase II Evaluation of a Novel Capecitabine Schedule in Combination with Lapatinib for Patients with HER2-Positive Metastatic Breast Cancer Refractory to Trastuzumab

Dose-dense therapy with paclitaxel via weekly 1-hour infusion: preliminary experience in the treatment of metastatic breast cancer

Phase II Study of Feasibility of Dose-Dense FEC Followed by Alternating Weekly Taxanes in High-Risk, Four or More Node-Positive Breast Cancer

TBCRC 011: Targeting the androgen receptor (AR) for the treatment of AR+/ER-/PR- metastatic breast cancer (MBC)

Safety of a novel capecitabine dosing schedule when combined with lapatinib in patients with HER2-positive metastatic breast cancer refractory to trastuzumab

A novel capecitabine dosing schedule combined with bevacizumab is safe and active in patients with metastatic breast cancer: A phase II study

Phase II trial of patupilone in patients (pts) with breast cancer brain metastases (BCBM) progressing or recurring after whole brain radiation therapy (WBXRT)

Standard chemotherapy (CMF or AC) versus capecitabine in early-stage breast cancer (BC) patients aged 65 and older: Results of CALGB/CTSU 49907

Phase I study of a novel capecitabine schedule based on Norton-Simon mathematical modeling

Suchergebnisse filtern